Time: 2024-08-19
In response to the monkeypox outbreak declared as a public health emergency by the World Health Organization , Fapon Biotech has been committed to providing innovative diagnostic solutions to address this emerging threat . The company has been continuously developing and upgrading its raw materials solutions for monkeypox antigen rapid tests since the outbreak in 2022 . The products developed by Fapon Biotech have high sensitivity , high specificity , and show no cross - reactivity with non - OPXVs such as the varicella - zoster virus . These solutions are designed to offer more effective and accessible testing options , particularly for low- and middle - income countries and regions , facilitating rapid diagnosis in such areas.
The increased global circulation of the Monkeypox virus in 2023 led to a higher demand for diagnostics , highlighting the need for simplified , automated , and accessible assays that are available outside laboratories . In response to this demand , the World Health Organization specified a target product profile for decentralized use , including in community settings . This initiative has encouraged more in - vitro diagnostics companies to develop Point - of - Care Testing ( POCT ) products that are convenient and accessible for screening and diagnosis in rural environments and areas with limited healthcare resources.
Amidst the ongoing battle against the spread of monkeypox , Fapon Biotech remains committed to leveraging its expertise to combat this global public health issue and support its global partners in the development of monkeypox diagnostic rapid tests . With over 20 years of experience in developing IVD solutions to prevent the spread of infectious disease agents , Fapon Biotech plays a crucial role in providing earlier detection and treatment for diseases such as HIV , hepatitis C , syphilis , malaria , dengue , and respiratory diseases.
Looking ahead , Fapon Biotech aims to continue supporting the development of diagnostic tests that offer earlier detection and treatment for the improvement of public health . The company 's extensive expertise in antibody design and cutting - edge technology positions it well to contribute to the fight against infectious diseases . Fapon Biotech invites collaboration and partnerships to further advance the field of in vitro diagnostics and deliver more accurate , convenient , and accessible diagnostics for everyone . For more information on how Fapon Biotech can assist or collaborate , interested parties can reach out via email at [ email protected]
Business
